New cell therapy for advanced solid tumors
Part of Cancer clinical trials.
This early-stage trial tests a new allogeneic cell therapy (WTX-212C) designed to fight advanced solid cancers. Researchers want to see if this treatment is safe and how well it works in patients whose cancer has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Advanced solid cancer confirmed by biopsy or tissue sample
- At least one tumor visible on imaging that can be measured
- Good overall health and ability to do light activities (ECOG score 0–1)
- Normal liver, kidney, and blood counts
- Expected to live at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy for people with advanced solid tumors (lung, liver, colorectal, or breast cancer). It aims to use your own immune cells to fight the cancer, and might help if standard treatments have stopped working.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
This trial tests an investigational cell therapy called GKL-006Allo for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can help shrink or slow the growth of tumors.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.